We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

207940:KRXSamsung Biologics Co.,Ltd. Analysis

Data as of 2026-09-08 - not real-time

₩1,440,000.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Samsung Biologics Co.,Ltd. trades at KRW 1,440,000.00, with its moving averages tangled rather than clearly stacked — a neutral trend structure. The last 30 days have lost 6.8%. Relative strength is 41.4 — neutral — and the MACD signal is bearish. Watch KRW 1,433,000.00 as support and KRW 1,645,000.00 as the nearer resistance level.
Multiples put this in undervalued territory: 29.3 times earnings against the sector's 30.6. Consensus targets land 36.6% above where the shares trade now. Revenue is growing at 30.2% on a 38.7% profit margin.
The composite risk read is 5/10, putting it in moderate territory. With 30-day volatility of 39.8%, a beta of 0.01 and a maximum drawdown of 36.7%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against buy longer out, with 6/10 conviction on the long call.

Top Market Events

Updated Jul 22, 2026 0 - Recorded Q2'26 revenue of KRW 1,321 billion and operating profit of KRW 586 billion -...media 1147690 Recorded Q2'26 revenue of KRW 1,321 billion and operating profit of KRW 586 billionDelivered stable...SEOUL dpa-AFX - PolyPeptide Group AG PPGN.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Trading below the 200-day average of 1576404.94
  • MACD momentum is negative
  • 30-day price change of -6.8%

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • P/E of 29.3 versus sector average of 30.6
  • Trading below the 200-day average of 1576404.94
  • Analyst targets imply +36.6% versus the current price

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • P/E of 29.3 versus sector average of 30.6
  • Analyst targets imply +36.6% versus the current price
  • Profit margin of 38.7% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth30.20%
Profit Margin38.75%
P/E Ratio29.3
ROE18.53%
ROA9.57%
Debt/Equity14.84
Op. Cash Flow₩2433.9B
Free Cash Flow₩1295.2B
Industry P/E30.6

Technical Analysis

TrendNeutral
RSI41.4
Support₩1,433,000.00
Resistance₩1,645,000.00
MA 20₩1,533,800.00
MA 50₩1,476,360.00
MA 200₩1,576,404.94
MACDBearish
VolumeStable
Fear & Greed Index94.11

Valuation

Fair Value₩986,467.16
Target Price₩1,967,520.00
Upside/Downside36.63%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta0.01
Volatility39.76%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskHigh
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.